comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 02:27:16 - browse：77

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： 7 more heat

WSS

Why Congress must ban federal programs from using QALYs

In 'major milestone,' FDA approves first cell therapy for solid tumors

WATCH: Why do our ears pop?

Ukraine seeks to reclaim its role as a hub for clinical trials

Driven by the pandemic, applicants flood public health schools

In 'major milestone,' FDA approves first cell therapy for solid tumors

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Anesthesiologist group: stop taking Ozempic before surgery

Driven by the pandemic, applicants flood public health schools

Trump demands the U.S. pay no more for drugs than other countries … again

Stanford president's case begs question: Who takes blame?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

7 more heat

Tori Bowie and the unacceptable rates of Black maternal death

Why Congress must ban federal programs from using QALYs

hotspot

Study identifies new proteins linked to dementia risk 25 years later

Awakening the world to the whoosh: A patient's crusade

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Flagship Pioneering startup Sonata Therapeutics lays off 21

Indian pharmaceutical industry in denial over drug

hotspot

explore

knowledge

Wikipedia